| Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer D Öhlund, A Handly-Santana, G Biffi, E Elyada, AS Almeida, ... Journal of Experimental Medicine 214 (3), 579-596, 2017 | 1913 | 2017 |
| Organoid models of human and mouse ductal pancreatic cancer SF Boj, CI Hwang, LA Baker, IIC Chio, DD Engle, V Corbo, M Jager, ... Cell 160 (1), 324-338, 2015 | 1897 | 2015 |
| Cytokines in clinical cancer immunotherapy P Berraondo, MF Sanmamed, MC Ochoa, I Etxeberria, MA Aznar, ... British journal of cancer 120 (1), 6-15, 2019 | 950 | 2019 |
| CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity Á Teijeira, S Garasa, M Gato, C Alfaro, I Migueliz, A Cirella, C de Andrea, ... Immunity 52 (5), 856-871. e8, 2020 | 468 | 2020 |
| BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial B Bockorny, V Semenisty, T Macarulla, E Borazanci, BM Wolpin, ... Nature Medicine 26 (6), 878-885, 2020 | 351 | 2020 |
| NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer IIC Chio, SM Jafarnejad, M Ponz-Sarvise, Y Park, K Rivera, W Palm, ... Cell 166 (4), 963-976, 2016 | 350 | 2016 |
| Interleukin-8 in cancer pathogenesis, treatment and follow-up C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz, Á Teijeira, C Oñate, ... Cancer treatment reviews 60, 24-31, 2017 | 318 | 2017 |
| Clinical presentation, diagnosis and staging of cholangiocarcinoma A Forner, G Vidili, M Rengo, L Bujanda, M Ponz‐Sarvisé, A Lamarca Liver International 39, 98-107, 2019 | 236 | 2019 |
| Paradigms on immunotherapy combinations with chemotherapy D Salas-Benito, JL Pérez-Gracia, M Ponz-Sarvisé, ME Rodriguez-Ruiz, ... Cancer discovery 11 (6), 1353-1367, 2021 | 220 | 2021 |
| Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry L Izquierdo-Sanchez, A Lamarca, A La Casta, S Buettner, K Utpatel, ... Journal of hepatology 76 (5), 1109-1121, 2022 | 142 | 2022 |
| An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer A Vallejo, N Perurena, E Guruceaga, PK Mazur, S Martinez-Canarias, ... Nature communications 8 (1), 14294, 2017 | 139 | 2017 |
| Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients ME Rodriguez-Ruiz, JL Perez-Gracia, I Rodriguez, C Alfaro, C Oñate, ... Annals of Oncology 29 (5), 1312-1319, 2018 | 116 | 2018 |
| TGFBI expression is associated with a better response to chemotherapy in NSCLC M Irigoyen, MJ Pajares, J Agorreta, M Ponz-Sarvisé, E Salvo, MD Lozano, ... Molecular Cancer 9, 1-12, 2010 | 94 | 2010 |
| Revisiting interleukin-12 as a cancer immunotherapy agent P Berraondo, I Etxeberria, M Ponz-Sarvise, I Melero Clinical Cancer Research 24 (12), 2716-2718, 2018 | 93 | 2018 |
| Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer I Baraibar, I Melero, M Ponz-Sarvise, E Castanon Drug safety 42, 281-294, 2019 | 91 | 2019 |
| TGFβ blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies ME Rodríguez-Ruiz, I Rodríguez, L Mayorga, T Labiano, B Barbes, ... Molecular cancer therapeutics 18 (3), 621-631, 2019 | 76 | 2019 |
| Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis R Zarate, J Rodriguez, E Bandres, A Patiño-García, M Ponz-Sarvise, ... British journal of cancer 102 (6), 987-994, 2010 | 75 | 2010 |
| Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma M Gonzalez-Cao, S Viteri, A Diaz-Lagares, A González, P Redondo, ... Oncology 74 (1-2), 12-16, 2008 | 67 | 2008 |
| Intratumoral nanoplexed poly I: C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors I Márquez-Rodas, F Longo, ME Rodriguez-Ruiz, A Calles, S Ponce, ... Science Translational Medicine 12 (565), eabb0391, 2020 | 64 | 2020 |
| Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance M Ponz-Sarvisé, PA Nguewa, MJ Pajares, J Agorreta, MD Lozano, ... Clinical Cancer Research 17 (12), 4155-4166, 2011 | 61 | 2011 |
